Search Within

Elisa De Stanchina

  1. "Lymphoma"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (5)
Groups
  1. Center for Hematologic Malignancies (16)
  2. Department of Medicine (16)
  3. Hematologic Malignancies, Division of (16)
  4. Lymphoma (16)
  5. Sloan Kettering Institute Postdocs (15)
  6. Executive Committee, Center for Hematologic Malignancies (13)

More Groups

People
  1. Anas Younes (13)
  2. Venkatraman Seshan (10)
  3. Zahra Asgari (10)
  4. Mariana Da Silva Ferreira (6)
  5. Patrizia Mondello (6)
  6. Ingrid Erazo Andrade (5)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (1)

More Years

Publications
  1. Blood (5)
  2. Cell Reports Medicine (2)
  3. Nature Communications (2)
  4. Cancer Discovery (1)
  5. Cancer Research (1)
  6. Cancers (1)

More Publications

Publishers
  1. American Society of Hematology (5)
  2. Cell Press (3)
  3. American Association for Cancer Research (2)
  4. Nature Publishing Group (2)
  5. Amer Soc Clinical Investigation Inc (1)
  6. Impact Journals (1)

More Publishers

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities
    Journal Article

    Fiore, D.; Cappelli, L. V.; Zhaoqi, L.; Kotlov, N.; Sorokina, M.; Phillip, J.; Zumbo, P.; Yoffe, L.; Ghione, P.; Wang, A.; more...
    Cell Reports Medicine (2025)

    Fulltext@MSK | Save
  • Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma
    Journal Article

    Portelinha, A.; da Silva Ferreira, M.; Erazo, T.; Jiang, M.; Asgari, Z.; de Stanchina, E.; Younes, A.; Wendel, H. G.
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Pharmacologically induced polyploidy triggers BCL2 dependence in lymphomas
    Meeting Abstract

    Portelinha, A.; da Silva Ferreira, M.; Erazo, T.; Asgari, Z.; de Stanchina, E.; Younes, A.; Wendel, H. G.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
    Journal Article

    Erazo, T.; Evans, C. M.; Zakheim, D.; Chu, K. L.; Refermat, A. Y.; Asgari, Z.; Yang, X.; Da Silva Ferreira, M.; Mehta, S.; Russo, M. V.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
    Journal Article

    Portelinha, A.; Thompson, S.; Smith, R. A.; Da Silva Ferreira, M.; Asgari, Z.; Knezevic, A.; Seshan, V.; de Stanchina, E.; Gupta, S.; Denis, L.; more...
    Cell Reports Medicine (2021)

    Fulltext@MSK | Save
  • Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition
    Journal Article

    Bala Tannan, N.; Manzari, M. T.; Herviou, L.; Da Silva Ferreira, M.; Hagen, C.; Kiguchi, H.; Manova-Todorova, K.; Seshan, V.; de Stanchina, E.; Heller, D. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A novel JAK1 mutant breast implant-associated anaplastic large cell lymphoma patient-derived xenograft fostering pre-clinical discoveries
    Journal Article

    Fiore, D.; Cappelli, L. V.; Zumbo, P.; Phillips, J. M.; Liu, Z.; Cheng, S.; Yoffe, L.; Ghione, P.; Di Maggio, F.; Dogan, A.; more...
    Cancers (2020)

    Fulltext@MSK | Save
  • Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
    Journal Article

    Mondello, P.; Tadros, S.; Teater, M.; Fontan, L.; Chang, A. Y.; Jain, N.; Yang, H.; Singh, S.; Ying, H. Y.; Chu, C. S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Dual inhibition of MCL1 and BCL2 in lymphoma using tumor targeted nanoparticles
    Meeting Abstract

    Bala, N. B.; Taghizadeh Manzari, M.; Da Silva Ferreira, M.; Asgari, Z.; Hagen, C.; Seshan, V.; de Stanchina, E.; Manova-Todorova, K.; Heller, D.; Younes, A.
    Blood (2019)

    Fulltext@MSK | Save
  • NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
    Journal Article

    Liu, Y.; Mondello, P.; Erazo, T.; Tannan, N. B.; Asgari, Z.; de Stanchina, E.; Nanjangud, G.; Seshan, V. E.; Wang, S.; Wendel, H. G.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save